Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Week, Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, Tolerability And Actual Use Of Bococizumab And An Autoinjector (Pre-filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia
Brief Summary: This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen).


Options:
A: Arm Label: Bococizumab 150mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 150mg | Arm Label: Bococizumab 75mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 75mg | Arm Label: Bococizumab 150mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 150mg placebo | Arm Label: Bococizumab 75mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 75mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg; Assigned to Arm(s): Bococizumab 150mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg; Assigned to Arm(s): Bococizumab 75mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg placebo; Assigned to Arm(s): Bococizumab 150mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg placebo; Assigned to Arm(s): Bococizumab 75mg placebo
B: Arm Label: alirocumab SAR236553 (REGN727) - Dose A; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Arm Label: alirocumab SAR236553 (REGN727) - Dose B; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Arm Label: alirocumab SAR236553 (REGN727) - Dose C; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Intervention Type: DRUG; Name: alirocumab SAR236553 (REGN727); Assigned to Arm(s): alirocumab SAR236553 (REGN727) - Dose A, alirocumab SAR236553 (REGN727) - Dose B, alirocumab SAR236553 (REGN727) - Dose C
C: Arm Label: Q28d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: 200mg PF-04950615 (RN316), Drug: 300mg PF-04950615 (RN316) | Arm Label: Q14d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: PF-04950615 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 200mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 300mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4

Answer: A